05.01.19
The US FDA sent a warning letter to Nutra Pharma Corp. for illegally marketing unapproved products labeled as homeopathic with claims about their ability to treat addiction and chronic pain, including pain associated with cancer, diabetes, shingles, fibromyalgia and other serious conditions. The products included topical treatments as well as an oral spray.
Specifically, FDA issued a warning letter to Nutra Pharma for: “Nyloxin Oral Spray,” “Nyloxin Topical Gel,” “Nyloxin Topical Roll-On,” “Nyloxin Topical Roll-On ES,” “Nyloxin Professional Size Pump Topical Gel” and “Regular Strength Sample Pack.” These products also may confuse consumers because its name is similar to FDA-approved drugs, said FDA.
The letter was sent following a review the company’s website at www.Nyloxin.com.
In its letter, FDA pointed to examples of claims on the company’s websites and social media website. FDA also pointed out issues with statements on the company’s Facebook and Twitter Social Media websites, and it had issues with the use of its logo and terminology.
Specifically, FDA issued a warning letter to Nutra Pharma for: “Nyloxin Oral Spray,” “Nyloxin Topical Gel,” “Nyloxin Topical Roll-On,” “Nyloxin Topical Roll-On ES,” “Nyloxin Professional Size Pump Topical Gel” and “Regular Strength Sample Pack.” These products also may confuse consumers because its name is similar to FDA-approved drugs, said FDA.
The letter was sent following a review the company’s website at www.Nyloxin.com.
In its letter, FDA pointed to examples of claims on the company’s websites and social media website. FDA also pointed out issues with statements on the company’s Facebook and Twitter Social Media websites, and it had issues with the use of its logo and terminology.
